KOC
NTLA icon

Koss-Olinger Consulting’s Intellia Therapeutics NTLA Stock Holding History

Koss-Olinger Consulting’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$94K – 302
2025
Q3 		$94K Hold
10,000
– – 0.01% 307
2025
Q2 		$93.8K Buy
+10,000
New +$82.1K 0.01% 310
2021
Q3 		– Sell
-8,000
Closed -$1.29M – 260
2021
Q2 		$1.29M Hold
8,000
– – 0.19% 58
2021
Q1 		$642K Buy
+8,000
New +$537K 0.11% 107

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Koss-Olinger Consulting's NTLA Position: Q4 2025 in Review

Koss-Olinger Consulting sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 10,000 shares — an estimated $94K sold.

Koss-Olinger Consulting first reported a position in NTLA in Q1 2021 and held it in 4 quarters. The position peaked at $1.29M in Q2 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Koss-Olinger Consulting reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Koss-Olinger Consulting sold 10,000 Intellia Therapeutics shares in Q4 2025, an estimated $94K.
  • Koss-Olinger Consulting first reported a position in Intellia Therapeutics in Q1 2021 and held it in 4 quarters.
  • Koss-Olinger Consulting's Intellia Therapeutics position peaked at $1.29M in Q2 2021.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Koss-Olinger Consulting's 13F filing for Q4 2025, filed 10 Feb 2026.